



THE UNIVERSITY OF  
**CHICAGO**  
BIOLOGICAL  
SCIENCES

**Anosmia -**

**The forgotten sense takes the center stage**

Jayant M. Pinto, M.D., F.A.C.S.

Professor of Surgery, Director of Research

Section of Otolaryngology-Head and Neck Surgery

Deans for Faculty Affairs, Biological Sciences Division

The University of Chicago

# Disclosures

- Research: NIH
- Advisory boards: Genentech, Sanofi-Genzyme/Regeneron, Optinose, GSK, Connect
- Clinical trials (site investigator): Sanofi Genzyme/Regeneron, Optinose, Connect
- Speakers Bureau: Sanofi-Genzyme/Regeneron, Optinose
- No other financial conflicts (stock, etc.)



"What's in a name? That which we call a rose  
By any other word would smell as sweet."

-William Shakespeare, *Romeo and Juliet*

- Special sense of olfaction is critical to human quality of life
- Early warning system
- Sensation of pleasure
- Potential role in kin recognition, pheromone detection, mood, central nervous system physiology, and other processes



# Great impairment in quality of life

- Impaired activities of daily living:
  - Detection of spoiled foods, smoke, gas leaks
  - Eating, cooking
  - Personal hygiene
  - Cleaning, buying fresh food
  - Socializing
- Increased symptoms of depression
- Reduced weight, appetite, & psychological well-being
- Overall decline in pleasure, quality of Life



# Olfactory loss is associated with major health problems

- AD and its precursor<sup>1</sup>, mild cognitive impairment<sup>2</sup>
- Brain pathology at autopsy<sup>3</sup>
- Future cognitive decline<sup>4</sup>
- Predates Parkinson's disease by ~4 years<sup>5</sup>
- Impaired in Lewy body dementia<sup>6</sup>
- A marker for neurodegeneration<sup>7</sup>
- Diabetes<sup>8</sup>, renal disease<sup>9</sup>, epilepsy<sup>10</sup>

---

<sup>1</sup>Schubert CR, 2008, Murphy C, 1990, <sup>2</sup>Devenand DP, 2010; <sup>3</sup> Attems J,1995; <sup>4</sup>Wilson RS, 2007; <sup>5</sup>Sobel N, 2001;


<sup>6</sup>Williams SS, 2009; <sup>7</sup>Hawkes C, 2003; <sup>8</sup>Weinstock RS, 1993; <sup>9</sup>Tung TH, 2005; <sup>10</sup>Kohler CG, 2001

# Decreased sense of smell predicts mortality



Olfactory dysfunction predicts 5-year mortality in older adults.  
Pinto JM, Wroblewski KE, Kern DW, Schumm LP, McClintock MK.  
PLoS One. 2014

# Poor sense of smell predicts mortality better than major common diseases



# Olfactory physiology


- Odorants diffuse up to roof of the nasal cavity
- Olfactory epithelium comprises the receptor surface
  - Superior portion of middle turbinate, superior turbinate, septum, cribriform plate
- Bathed in a blanket of mucus produced by Bowman's glands which protect and carry escort molecules
- Only portion of the body where nerve tissue is directly exposed to the environment
  - Susceptible to injury, effects of airborne allergens, pollutants, viruses
  - Conduit to the CNS





# Olfactory epithelium

- Neuronal receptor cells (Cranial Nerve I)
- Supporting or sustentacular cells
- Stem cells



# Olfactory receptors neurons

- 6 – 10 million ciliated receptor neurons in each nasal cavity
- Large surface area to detect odorants
- Binding of odorants to the receptors at the cell membrane activate the signaling cascade



# How do we smell?

- Sniffing
- Odorants diffuse into the mucus and are transported to the olfactory receptor by chaperones called odorant binding proteins
- Receptor binding then induces signaling



# Olfactory Receptors


Axel and Buck 1991

Discovery of Olfactory  
Receptor Gene Family

Ancient, large gene  
family

A physical and coding  
basis for the sense of  
smell

# ORs are present on every chromosome: An ancient part of our physiology



Genetic variation  
can affect  
olfactory function  
and perception.

(Keller, Pinto,  
others)



# Pathology of the olfactory system

- Numerous causes of olfactory dysfunction
    - Inflammatory
    - Trauma
    - Congenital
    - Degenerative
    - Endocrine
    - Neoplastic
  - Disease in the nose, the nervous system, or systemic disease
  - Conductive
    - Hindered access of odorants to neuroepithelium
  - Sensorineural
    - Perturbation of neuronal elements
  - Central
    - Brain disease
-

# Nomenclature of olfactory dysfunction

- General or total anosmia
    - Inability to detect any qualitative olfactory sensation
  - General or total hyposmia
    - Decreased sensitivity to all odorants
  - Specific anosmia
    - Inability to detect a specific odorant
  - Dysosmia
    - Distorted sensation
  - Phantosmia
    - Phantom sensation
  - Hyperosmia
    - Increased sensitivity
-

# Common causes

- Most common
    - Age
    - \*URI
    - \*Rhinosinusitis
    - \*Trauma
  - Others
    - Surgery
    - Neurodegenerative disease
  - Rare
    - Chemical injury/toxin exposure
    - Endocrine disease
    - Tumors
-



# Measuring olfaction

- Many people are unaware of deficits: **you must perform objective testing**
  - Tests allows
    - Assessment of degree of loss
    - Establishment of validity of disease (rule out malingering)
    - Monitoring of changes over time
  - A variety of methods
    - Odor identification
      - UPSIT, Sniffin' Sticks most commonly used
      - Cross cultural versions (some not validated)
    - Threshold testing
    - Odor Discrimination (research)
    - Neurophysiologic techniques (research)
-

# University of Pennsylvania Smell Identification Test (UPSIT)

- 40 item scratch and sniff smell test
- Validated in cross-cultural populations
- Test-retest reliability > .90
- Cheap(ish), but not reusable
- Age and sex norms available


<http://www4.parinc.com/Products/Product.aspx?ProductID=SIT>

# Relevant history

- History
  - Onset, rate of decline, duration
- Nasal symptoms
  - Inflammatory disease
    - AR, CRS
  - Facial or head trauma
  - Prior surgeries (sinus, brain)
- Neurologic symptoms
- Family history for genetic syndromes
  - Kallmann's syndrome
  - Bardet-Biedl syndrome
  - Extremely rare
- New/current/past medications
- Viral infection
- Occupational exposures
- Diet (malnutrition)
- Use of tobacco, alcohol
- Drugs
  - Medication side effects (psychiatric, anti-cancer, statins)
  - Illicit drugs (cocaine, heroin)
  - Intranasal zinc preparations

# Physical examination/testing

- Thorough nasal examination including endoscopy
  - Inflammatory disease (CRS, nasal polyposis)
  - Nasal tumors (esthesioneuroblastoma, etc.)
- Careful Head and Neck
- Complete neurologic exam
  - Cranial nerves
  - Memory



# Treatment of olfactory dysfunction

- Best outcome: Conductive disease
    - Allergy therapy
      - Immunotherapy
      - Systemic (antihistamines, antileukotrienes, decongestants)
      - Intranasal (steroids, antihistamines)
        - Nebulized or vertex to floor delivery is better
    - Surgery
      - Septoplasty, Endoscopic Sinus Surgery
-

# Treatment of olfactory dysfunction

- Sensorineural dysfunction is very difficult to treat
  - Treat associated diseases
    - Autoimmune disease, diabetes, renal dysfunction, etc.
  - Nutritional support
    - Vitamin A, b carotene, Thiamine (few are deficient)
    - No good studies, but probably no harm
  - Olfactory training may be helpful
    - Daily exposure to odors may stimulate olfactory stem cell growth/brain plasticity
-

# Treatment of olfactory dysfunction

- Counseling regarding detection of spoiled food, installation of smoke detectors and monitoring for gas leaks
- Emphasize other characteristics of foods
  - Texture, temperature, visual appeal



# Causes of respiratory infection related smell loss

- Bacteria
  - Fungi
  - Rare organisms such as microfilaria
  - Most commonly: respiratory viruses
    - Common cold (Rhinovirus and Adenovirus)
    - Influenza
    - And now: SARS-CoV-2
  - Post-viral olfactory dysfunction/anosmia
- 







The global overall prevalence (Bartheld, et al)

Smell disorder: 43.0%

Taste disorder: 44.6%





# Smell dysfunction is common in COVID-19, but many remaining questions


- Presence of decreased smell higher in Europe/North America vs. Asia
  - Differences in variants?
  - Differences in receptor genetic variation?
- Nearly all data is by self report (notoriously inaccurate)
- Some data show higher prevalence with objective testing:
  - 76 vs. 53%
- Confounded by disease context
  - Hospitalized vs. outpatient, sick vs. well
  - Confirmed disease vs. report
  - Many other factors
  - Cohort studies underway to study survivors with objective testing
  - Few prospective studies
    - UChicago cohort




# Mechanisms for COVID-19 smell loss

- ? sensorineural vs. conductive cause
- No correlation of olfactory severity with other symptoms
- Many patients have olfactory loss without other nasal symptoms
- Edema of the olfactory clefts (OC) on MRI
  - impair odorant access to the sensory epithelium
  - without obvious nasal obstruction
- IL-6 is associated olfactory neuron dysfunction
- Olfactory epithelium of COVID-19 patients in autopsy
  - prominent leukocytic infiltration
  - possible cause of neuritis and axonal damage of olfactory nerve





# Genomic studies show SARS-CoV-2 receptor expression on support cells, not olfactory neurons



ACE2 protein (green) is detected in sustentacular cells and KRT5-positive HBCs (red; white arrowhead). Nuclei were stained with DAPI (blue).



# Effects on regeneration

- Damage to the olfactory epithelium via olfactory sensory neuron apoptosis
- Inhibition of olfactory neurogenesis and thus poor recovery
- Transition to respiratory epithelium
- An important model of post-viral smell loss from SARS-CoV-2



# Treatment of COVID-19 olfactory dysfunction

- No pharmacologic treatments for post-viral smell loss
    - systemic steroids
    - intranasal steroids
  - Smell training
  - Supportive care
  - Testing
    - Best chance of recovery at 1 year
    - Some recover event at 2-3 years
    - Objective testing allows better counseling
      - patient resilience/relief
- 





# Inflammatory disease and the sense of smell

- Sinonasal disease: one of the most common causes of olfactory impairment
- The prevalence of chronic sinusitis approaches 20 percent of US adults (defined by > 12 weeks of classic symptoms)
- The prevalence of allergic rhinitis is 10-30% in US, similarly high prevalence in industrialized countries
- For clinicians that treat olfactory disorders, this is an exciting area because the problem is reversible and we have treatments
- Thus, taking a 'looking for the keys under the light' approach, asking patients about inflammatory disease is a key first step in approaching patients with this problem



# Loss of olfaction is a cardinal symptom in CRS

- 60-80% of patients report some form of olfactory dysfunction
  - Typically hyposmia, but can be dysosmias also
- Prevalence is high using objective testing
  - 67% using 40-item UPSIT
  - 78% using Sniffin' Sticks (TDI)
- Up to 25% of patients do not recognize the loss
  - Gradual nature?



# Key mechanism in CRS: Inflammation

- Consequently, factors that increase sinonasal inflammation are highly associated with olfactory impairment in CRS
- These include:
  - Smoking
  - Nasal polyposis (most severe form of CRS)
  - Asthma
  - Tissue eosinophilia



# Conundrum: conductive vs. sensorineural?

- Physical obstruction of the olfactory cleft by nasal polyp or mucosal edema impairs airflow to the olfactory cleft.
- However, increased tissue eosinophilia appears to have a local, damaging impact by release cytotoxic substances to the olfactory neuroepithelium.
  - Direct effects on olfactory neurons/support cells
  - Consistent with this, disease features which mark heightened inflammation are associated with higher rates of olfactory impairment
    - Serum eosinophilia
    - Asthma
- Other forms of inflammatory disease (CRS without nasal polyposis) affect the sense of smell less commonly (only 17% by objective testing) and less severely
  - Less responsive to medical therapy



# How does CRS cause olfactory impairment?

- Both conductive and sensorineural components
  - Decreased odorant signaling, reduced detection of odors
- Specific inflammatory mediators appear important
  - Eosinophils and their products (ECP, etc.)
  - Cytokines: IL-2, IL-5, IL-6, IL-10, and IL-13
- This inflammatory environment may stimulate the intracellular tumor necrosis factor- $\alpha$ /c-Jun-N-terminal kinases pathway
  - Deleterious effects on neuronal function
  - Leads to apoptosis and cell death
  - Inhibition of this pathway may have neuroprotective effects
- Structural effects on the olfactory system
  - Decrease in size and function of the olfactory bulb (similar to post viral anosmia)
  - Cause or effect?





# Assessing what's happening in the olfactory cleft

- Mucus from sampled from patients with CRS and controls
- Proteome measured by liquid chromatography and mass spectrometry
- Pathway enrichment analysis
- Significant differences were found between patients with normosmia and those with dysosmia for a number of **odorant binding proteins** and **metabolizing enzymes**




# Do intranasal steroids affect the olfactory cleft in allergic rhinitis?









# Similar results in CRS when examining superior turbinate eosinophilia



# Machine learning as a tool to study predictors of olfactory function in CRS

- Examination of 4 ML methods used to analyze 611 adults with CRS in a prospective, multi-institutional, observational cohort study
- Predictors included: objective disease measures (CT and endoscopy scores), age, sex, prior surgeries, socioeconomic status, steroid use, polyp presence, asthma, and aspirin sensitivity
- In a prospective cohort study, 37 parameters from four categories were recorded from 60 men and 98 women before and four months after endoscopic sinus surgery
  - endoscopic measures of nasal anatomy/pathology, assessments of olfactory function, quality of life, and socio-demographic or concomitant conditions. Parameters containing
- Changes in the endoscopic Lildholdt score allowed separation of baseline from postoperative data accurately.
- Another method of analyzing complex data!



# Workup of olfaction in the context of CRS

- Subjective measures
  - Visual analogue scales
  - Sinonasal outcome test (SNOT-22)
  - Rhinosinusitis disability index (RSDI)
  - Olfactory-specific, QOL measures
    - Questionnaire of olfactory disorders-negative statements (QOD-NS)
    - Good internal consistency and test-retest
- But, essentially all are subjective measures
  - Poor correlation with testing
- Psychophysical testing is the gold standard (discussed in other parts of this meeting)
  - Orthonasal is common



# Novel measures: Imaging

- Imaging of the olfactory cleft/olfactory bulb can be helpful diagnostic tools to assess olfactory dysfunction in CRS
- Computed tomography (CT) imaging is a standard tool to assess sinonasal mucosal inflammation in patients with CRS and plan surgery
  - The degree of radiologic opacification in the olfactory cleft on CT correlates with the degree of olfactory loss in CRS
  - Stronger in patients with CRS with nasal polyposis compared those without
- Other methods of assessing olfactory cleft inflammation: validated endoscopic scoring system that reliably correlates with objective olfactory function
  - Easily performed in routine evaluations for patients with CRS



# Imaging the olfactory system in CRS

- MRI is useful for viewing the central olfactory system
  - Detailed imaging of the olfactory apparatus: the olfactory bulb (OB), olfactory tract, sulcus, and the central olfactory projection areas
- OB size correlates with olfactory loss in patients with CRS
- This appears to be plastic: changes in size of the OB in accordance with the current olfactory status in patients with CRS
  - Patients with CRSwNP undergoing endoscopic sinus surgery (ESS) had objectively improved olfaction and postoperative increase in olfactory bulb volume size
  - Some hope!



# Patients with CRS with severe olfactory dysfunction show differences in central olfactory regions

Reduced GMV in the gyrus rectus, orbitofrontal cortex, thalamus, and the insula.



# Outcomes of olfaction with medical therapy

- Meta-analysis of randomized controlled trials (RCTs) evaluating olfactory outcomes after oral steroid treatment in patients with CRSwNP
- 4 RCTs found that a subjective improvement in olfaction compared with placebo out to 6 months max, so durability of response could not be assessed
- 2 RCTs demonstrated short-term smell improvement with a 2-week follow-up
- Evidence also suggests that the degree of olfactory response following the use of oral glucocorticoids correlates with the degree of olfactory improvement following ESS
- These medicine have major side effects in the long term, however,
- One protocol is oral steroids, followed by topical
- New steroid delivery systems and biologics offer new opportunities





# New treatments for CRS that improve olfaction

- Novel steroid delivery systems
  - Optinose (Xhance)
- Biologics
  - Anti-IL4R $\alpha$  (Dupilumab)
  - Anti-IgE (Omalizumab)
  - Anti-IL-5 (Mepolizumab)
  - Anti IL-5R $\alpha$  (Benralizumab)
  - Others coming:
    - Anti-TSLP (Tezepelumab)



# Outcomes with surgery

- Functional endoscopic sinus surgery for CRS results in improved olfaction as measured objectively
  - Greatest improvement for women, patients with nasal polyps, and those with aspirin intolerance
  - Consistent with greatest improvement with increased T2 immune responses
- Similar olfactory related quality of life improvements
  - Soler demonstrated a significant improvement in postoperative QOD-NS scores.
  - Baseline severity of disease scores by imaging predicted postoperative changes in QOD-NS scores
- A recent meta-analysis demonstrates postoperative improvements in measures of olfaction in 23/24 studies
  - either objective or subjective testing
- These results vary by patient factors, extent of disease, extent of surgery, differences in postoperative treatment, and others



# Results after sinus surgery

- Improvement of olfaction specific QoL was also established in a multi-center prospective study
- Preoperative lesions in the olfactory cleft are associated with poor olfactory outcomes
- Overall, 65% will realize a clinically meaningful improvement in QoL after ESS
- Patients undergoing their first sinus surgery are twice as likely to improve as patients undergoing revision



# New data collection tools: MySinusitisCoach

## Real-life study

N = 626 users of mySinusitisCoach  
CRSwNP/CRSsNP: 51.8%/48.2%  
History of FESS: 52.2%  
Asthma: 32.2%


## Mobile application




Cross-sectional evaluation  
of patient-reported outcome measures  
in CRS patients

## Key findings

### Burden of uncontrolled disease in CRS



### FESS improves patient outcomes but not in patients with history of FESS >3



# Comparison of medical versus surgical management

- Deconde examined 281 medically refractory CRS patients who were candidates for ESS.
- 20% of patients elected to continue medical management, whereas 80% chose to undergo ESS
- Both groups experienced statistically significant improvement in objective testing for olfactory dysfunction
- Prior ESS was the only risk factor associated with failure of postoperative olfaction
  - An indicator of refractory disease, elevated inflammation, or consequence of surgery?

# Conclusions

- We can exploit our ability to manipulate disease in patients with CRS to study olfaction in humans
- New tools (therapies, surgeries, technologies, analytic methods) offer the ability to improve our ability to reverse olfactory dysfunction in these patients
- Human disease may be a model to understand how inflammation affects the olfactory systems
- Perhaps we can use this information to design therapies for other forms of olfactory disorders



# Acknowledgments

## **The University of Chicago**

### **The Olfactory Research Group (The ORG)**

Psychology/Comparative Human  
Development

Martha K. McClintock

Public Health Sciences

Kristen E. Wroblewski

L. Philip Schumm

Geriatrics/Palliative Care

Megan Huisinigh-Scheetz

William Dale (now City of Hope)

Pritzker School of Medicine

Yazan Eliyan

Matthew GoodSmith

Otolaryngology-Head and Neck Surgery

Dara Adams

## **Boston University**

Jennifer Weuve

## **Rush University**

David A. Bennett

## **Michigan State University**

Honglei Chen



## **Funding**

NIA: AG030481, AG036762, AG029795

NIEHS: ES022657



THE UNIVERSITY OF  
**CHICAGO**  
MEDICINE &  
BIOLOGICAL  
SCIENCES